Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees

Francesca

Francesca Aulenta, Mannheim DE

Patent application number	Description	Published
20090160077	AQUEOUS BINDER FOR FIBROUS OR GRANULAR SUBSTRATES - Aqueous binders for fibrous and granular substrates, based on itaconic acid copolymers.	06-25-2009
20100240923	ENZYMATIC SYNTHESIS OF (METH)ACRYLIC ESTERS OF HYDROXY-FUNCTIONAL AROMAS - A process for preparing (meth)acrylic esters (F) of hydroxy-functional aromas (A), in which at least one hydroxy-functional aroma (A) in the presence of at least one enzyme (E) is esterified with (meth)acrylic acid (S), or transesterified with at least one (meth)acrylic ester (D), the reaction in the case of the transesterification being effected in the absence of solvents.	09-23-2010
20110015285	FOAMABLE COPOLYMERS BASED ON RENEWABLE RAW MATERIALS - The invention relates to a process for the production of foamable copolymers, to foamable copolymers and to foamable polymer structures based on itaconic acid, mesaconic acid, fumaric acid, maleic acid, aconitic acid, and glutaconic acid.	01-20-2011
20110098372	FOAMABLE POLYAMIDES - Thermoplastic molding compositions comprising	04-28-2011
20120016114	PROCESS FOR THE PREPARATION OF MONOETHYLENICALLY UNSATURATED GLYCOSYLAMINES - The present invention relates to a process for the preparation of monoethylenically unsaturated glycosylamines, in which an aldehyde sugar is reacted with a primary aliphatic amine or ammonia in aqueous medium and, without interim isolation, is reacted with the anhydride of a monounsaturated carboxylic acid, or an aldehyde sugar is reacted directly with allylamine, and to a process for the preparation of polymers which comprise N-acylated glycosylamine groups in copolymerized form, and to novel unsaturated N-maleinylated glycosylamines.	01-19-2012

Francesca Bagatin, Rovello Porro IT

Patent application number	Description	Published
20120010399	Biotechnological Production of Chondroitin - Chondroitin is produced by culturing a recombinant microorganism which is obtained by inactivation of a gene encoding an enzyme responsible for addition of fructose residues to the linear chondroitin polysaccharide in a microorganism producing a fructosylated derivative of chondroitin.	01-12-2012

Francesca Baione, Milano IT

Patent application number	Description	Published
20100059158	TIRE FOR VEHICLE WHEELS COMPRISING AN IMPROVED ELASTOMERIC COMPONENT - A tire for vehicle wheel includes at least one elastomeric component including a crosslinked elastomeric material obtained by crosslinking an elastomeric composition including at least one diene elastomeric polymer; at least one sulfur-based vulcanizing agent, and at least one adhesion promoting agent having formula HOOC—R—S—R′—COOH wherein each of R and R′, equal or different from each other, is a divalent organic group. In a preferred embodiment of the first aspect of the present invention, the elastomeric component includes a metal reinforcing agent embedded therein.	03-11-2010
20100069529	TIRE AND CROSSLINKABLE ELASTOMERIC COMPOSITION - A tire includes at least one structural element including a crosslinked elastomeric material obtained by crosslinking a crosslinkable elastomeric composition including: (a) an amount higher than or equal to 30 phr, preferably 40 phr to 100 phr, of at least one polyisoprene rubber; (b) an amount lower than or equal to 70 phr, preferably 0 phr to 60 phr, of at least one diene elastomeric polymer other than the polyisoprene rubber (a); (c) an amount higher than or equal to 30 phr, preferably 40 phr to 120 phr, of at least one carbon black reinforcing filler; (d) 0.2 phr to 10 phr, preferably 1 phr to 5 phr, of at least one copolymer of at least one ethylenically unsaturated carboxylic acid or a derivative thereof with at least one ethylenically unsaturated monomer containing at least one polyoxyalkylene side chain. Preferably, the structural element is a tire's sidewall.	03-18-2010
20100089512	PROCESS FOR PRODUCING AND STORING A SEMI-FINISHED PRODUCT MADE OF ELASTOMERIC MATERIAL - A process for producing tyres for vehicle wheels includes the following steps: manufacturing a green tyre including at least one element made of crosslinkable elastomeric material, the element being obtained by unwinding a semi-finished product in strip form from a storage reel and then coiling the product onto a building drum; moulding the green tyre in a moulding cavity defined in a vulcanizing mould; crosslinking the elastomeric material by heating the tyre to a given temperature for a given time; wherein the element made of crosslinkable elastomeric material includes at least one copolymer of at least one ethylenically unsaturated carboxylic acid or a derivative thereof with at least one ethylenically unsaturated monomer containing at least one polyoxyalkylene side chain.	04-15-2010

Francesca Boato, Tegna CH

Patent application number	Description	Published
20100015173	COILED-COIL LIPOPEPTIDE HELICAL BUNDLES AND SYNTHETIC VIRUS-LIKE PARTICLES - The invention relates to lipopeptide building blocks consisting of a peptide chain comprising a coiled-coil domain, linked covalently to a lipid moiety comprising long alkyl or alkenyl chains, and optionally linked to an antigen; and to helical lipopeptide bundles and synthetic virus-like particles formed by aggregation. The nanometer size and shape of these bundles and particles, their stability under aqueous physiological conditions, their chemical composition, the possibility to incorporate B- and T-cell epitopes, and their production by chemical synthesis, make them highly suitable as vaccine delivery vehicles.	01-21-2010

Francesca Borgo, Milano IT

Patent application number	Description	Published
20080206295	Formulations Based on 3-Iodo-2-Propynyl Butyl Carbamate - Formulations in water suspension of microcapsules based on 3-iodo-2-propynyl butyl carbamate (IPBC) comprising (parts by weight): (a) 10-60 parts of polymeric microcapsules comprising inside them IPBC and a synergizing agent formed of one or more alkylbenzenes having a number of carbon atoms from 9 to 20: (2) 1-5 parts of one or more dispersants; (3) 1-20 parts of one or more excipients selected from thickeners, antifoam, antifreeze, in can preservative agents; (4) water to 100.	08-28-2008

Francesca Borgo, Lainate IT

Patent application number	Description	Published
20100173781	METHOD FOR MODULATING THE RELEASE RATE OF MICROENCAPSULATED ACTIVE INGREDIENTS - A method for modulating the release rate of microencapsulated active ingredients comprising the following steps: I) preparation of an aqueous suspension A) comprising microcapsules of at least one active ingredient, II) preparation of a liquid emulsifiable in water, component B), comprising a solvent of the active ingredient and at least a surfactant, III) water, component C), for diluting to the application dose the active ingredient, and mixing A), B) and C).	07-08-2010

Francesca Borgo, Rho IT

Patent application number	Description	Published
20110312496	PESTICIDES FORMULATIONS - Concentrated microemulsions comprising: 1) 10-25 parts by weight of a pesticide with a solubility in water at 20° C. lower than 1% l by weight and having a melting point from 10° C. to 60° C.; 2) 8-25 parts by weight of one or more solvents containing oxygen atoms, having a solubility in water at 20° C. lower than 5% by weight and the Hildebrand solubility parameter in the range 16-21 MPa	12-22-2011

Francesca Buttini, Parma IT

Patent application number	Description	Published
20100233276	COMPOSITIONS IN POWDER FORM MADE OF SOFT AGGLOMERATES OF A MICRONIZED DRUG AND OF A TWO-COMPONENTS EXCIPIENT, AND PROCESS FOR THEIR PREPARATION - The described agglomeration of drug microparticles blended with excipient microparticles is a technique for the size enlargement of micronized products that could be damaged by granulation or compaction techniques. These agglomerates can be used as oral prompt or delayed-release dosage forms administered as they are or dispersed in a liquid. The composition and quantity of the excipient microparticles resulted to be the crucial factors for the agglomerate quality. Therefore, adjusting the content of surface-active agent between 8-20%, of the excipient microparticles it is possible to agglomerate microparticles of drugs that could not be agglomerated per se. Increasing the surfactant concentration in the spray-dried excipient microparticles or increasing the fraction of these excipient microparticles in the blend, the agglomeration was improved. The spray drying technique concentrates the surface-active agent on the microparticle surface. By tumbling, the surface-active agent present on microparticles excipient surface was spread to fill the inter-particle interstices of drug particles giving rise to more resistant agglomerates. This phenomenon occurred also by vibration; the production in this case was quicker.	09-16-2010
20110097409	PARTICLES COMPRISING A SALT OF 8-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]-2(1H)-Q- UINOLINONE HAVING IMPROVED ADHESION PROPERTIES FOR POWDER FORMULATIONS FOR INHALATION - Powder particles comprising a pharmaceutically acceptable salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone (carmoterol) having a specific properties exhibit improved adhesion properties for dry powder formulations for inhalation. Such particles are useful for formulations in the form of powders for inhalation and the treatment of certain conditions and diseases.	04-28-2011

Francesca Canessa, Genova IT

Patent application number	Description	Published
20100049724	PROCESS AND A SYSTEM FOR UPDATING A DATA STRUCTURE IN A RELATIONAL DATABASE USED WITHIN A MANUFACTURING EXECUTION SYSTEM - A process for updating a data structure in a relational database used within a manufacturing execution system, contain the steps of defining within the database the data structure and defining SQL scripts having specific rules. The rules contain a header describing an initial data structure and a final data structure, thereby defining each of the defined SQL scripts as a section of the updating process. The current data structure of the database is analyzed and the required sections among the sections available are identified by comparing the current data structure of the database to the initial data structure defined in the header of the SQL script. A sequence order to apply the sections is defined and the required SQL scripts are run according to the defined sequence order. This allows developers to define the SQL script for their own demands without coordinating the requested changes with other development groups.	02-25-2010

Francesca Cardullo, Verona IT

Patent application number	Description	Published
20080269195	Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine - Compounds of formula (I) or a salt thereof are disclosed:	10-30-2008
20090192194	Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them - A compound of formula (I)	07-30-2009
20090326011	AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS - Disclosed herein are compounds of formula (I)	12-31-2009
20100197699	I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders - The present invention relates to novel compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof,	08-05-2010

Francesca Ceccacci, Roma IT

Patent application number	Description	Published
20100035796	17-ALPHA-SUBSTITUTED DERIVATIVES OF ESTRADIOL WITH WOUND-HEALING ACTIVITY - The invention relates to 17α-(5-hydroxy-C	02-11-2010

Francesca Chiodi, Stockholm SE

Patent application number	Description	Published
20100233157	HUMAN ANTIBODIES AGAINST HUMAN FAS AND THEIR USE - Binding members directed to human Fas (Fas), in particular antibody molecules against human Fas, employing the antibody VH and/or VL domain of the antibody molecule termed F45D9, which may be in IgG1 or IgG4 format. Methods of use in patients, diseases or disorders involving apoptosis, such as Graft-Versus-Host Disease, HIV-infection, Stevens-Johnson syndrome or Toxic epidermal necrolysis, Islet transplantation as treatment for insulin-dependent diabetes, diseases based on ischemia or ischemic reperfusion injury, heart disease, renal disease, neurological disorders and injuries and lymphocyte depletion in cancer patients associated to cytotoxic antineoplastic therapy.	09-16-2010

Francesca Cordeiro, London GB

Patent application number	Description	Published
20100278747	CARRIER - The invention relates to a carrier for delivering agents to the posterior region of the eye, the carrier comprising a Vitamin E derivative, especially tocopherol. The carrier may also comprise a cell death marker, such as an annexin.	11-04-2010
20100284922	MARKER - The invention relates to the use of a cell death marker labelled with a wavelength-optimised label for identifying cell death in the eye. Suitable cell death markers are the Annexins and fragments and derivatives thereof. The invention also relates to a pharmaceutical composition comprising a cell death marker labelled with a wavelength-optimised label and a method for monitoring cell death in the eye using a cell death marker labelled with a wavelength-optimised label.	11-11-2010

Francesca Curreli, Bronx, NY US

Patent application number	Description	Published
20090281041	ANTIVIRAL CELL-PENETRATING PEPTIDES - Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.	11-12-2009
20100035912	Small Molecule Inhibitors of Retroviral Assembly and Maturation - Chemical compounds that disrupt retroviral assembly and maturation are presented herein. More particularly, this disclosure provides small molecule compounds that disrupt the formation and maturation of virus particles and methods of using such small molecules to treat HIV-1 infection.	02-11-2010

Francesca De Amicis, Buttrio IT

Patent application number	Description	Published
20110041222	ARTIFICIAL DNA SEQUENCE WITH OPTIMIZED LEADER FUNCTION IN 5' (5'-UTR) FOR THE IMPROVED EXPRESSION OF HETEROLOGOUS PROTEINS IN PLANTS - A nucleotide leader sequence 5′-UTR comprises elements favorable to gene expression, such as repeated CAA trinucleotide elements in combination with repeated CT dinucleotide elements.	02-17-2011

Francesca De Ferra, Lodi IT

Patent application number	Description	Published
20080311577	Method for the Identification of Sulfo-Oxidizing Bacteria and for the Monitoring of Elemental Sulfur in the Environment - A method is described for the identification of sulfooxidizing bacteria comprising the extraction of the DNA from environmental samples and the subsequent identification of at least one fragment of the Thio 16S gene or SoxB gene present in these bacteria. The method can be used for determining the level of elemental sulfur in samples of soil.	12-18-2008
20100184060	METHOD FOR THE IDENTIFICATION OF PROPANE-OXIDIZING BACTERIA - The invention relates to a method for the identification of propane-oxidizing bacteria which is based on the identification of at least one fragment of the prmA gene encoding the alpha subunit of the propane monooxygenase enzyme and/or the prmD gene encoding an ancillary protein involved in the oxidation reaction of propane by gene amplification in the presence of pairs of primers selected in correspondence of homologous portions, deduced from the alignment of the prmA and prmD sequences.	07-22-2010
20110020913	PROCESS FOR THE PRODUCTION OF ALGAL BIOMASS WITH A HIGH LIPID CONTENT - The invention relates to a process for the production of algal biomass with a high lipid content, comprising: (a) the production of inocula in order to effect phase (b), in photoreactors; (b) the massive cultivation of the algal biomass in open ponds, inoculated with phase (a); (c) a thickening phase of the algal biomass, effected blandly; (d) an induction phase of the lipid production, wherein modules are used consisting of photoreactors or open ponds; (e) a separation phase of the biomass with a high lipid content.	01-27-2011

Francesca Demichelis, New York, NY US

Patent application number	Description	Published
20110034677	RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.	02-10-2011

Francesca Demichelis, Cambridge, MA US

Patent application number	Description	Published
20090004652	Methods for identifying and using SNP panels - Described are methods for identifying single nucleotide polymorphism (SNPs) that are useful for analyzing genetic samples, and for using said SNPs to determine genetic identity of samples.	01-01-2009
20100137164	BIOMARKERS FOR PREDICTING PROSTATE CANCER PROGRESSION - The present invention relates to the identification and use of gene expression profiles with clinical relevance to prostate cancer. In particular, the invention provides the identity of genes whose expression, at the transcriptional and protein levels, is correlated with prostate cancer progression. Methods and kits are described for using these gene expression profiles in the study and/or diagnosis of prostate cancer diseases, in the prediction of prostate cancer progression, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that target these genes or their protein products, in particular for the development of therapeutics for modulating prostate cancer progression.	06-03-2010

Francesca Di Modugno, Rome IT

Patent application number	Description	Published
20120028252	HUMAN MENA ISOFORMS SERVE AS MARKERS OF EPITHELIAL TO MESENCHYMAL TRANSITION AND SENSITIVITY TO EGFR INHIBITION IN HUMAN CANCER CELLS - The present invention discloses a method for discriminating between sensitive and resistant tumours to a treatment with EGFR inhibitor drugs comprising: in vitro testing whether tumour material expresses the hMena	02-02-2012

Francesca Di Modugno, Missaglia (lc) IT

Patent application number	Description	Published
20110316307	CRASH BOX - A crash box (	12-29-2011

Francesca Dinon, Trieste IT

Patent application number	Description	Published
20090253651	DRUG DELIVERY SYSTEM BASED ON REGIOSELECTIVELY AMIDATED HYALURONIC ACID - New drug delivery systems (DDS) are described containing hyaluronic acid and a therapeutic agent, wherein the therapeutic agent is linked, directly or via a linker, to 6-aminohyaluronic acid and where the linkage of the drug or linker with 6-aminohyaluronic acid is realised by an amide bond. Preferred therapeutic agents for use in the present DDS are anti-inflammatory, antibiotic, antitumor drugs. Preferred linkers are: succinic acid, succinic acid linked to aminoacids, succinic acid linked to peptides. The DDS are stable and free of undesired reaction by-products and impurities, and show a high level of pharmacological efficacy.	10-08-2009

Francesca Doonan, Cork IE

Patent application number	Description	Published
20110136898	TREATMENT OF RETINAL DEGENERATION - The use of a compound of general formula (I): or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a disease or condition characterised by apoptosis or degeneration of mammalian cells, wherein: R1 is a alkoxy, alkyl, ether or ester group; R2 is H or has the formula wherein Y is linear or branched, saturated or unsaturated, aliphatic group with from 2 to 23 carbon atoms, or a cyclic group, and which can contain substituents selected from the group consisting of hydroxyl, alkoxy, amino, carboxyl, cyano, nitro, alkylsuphonyl or halogen atoms, X is O or S; and R3 is any substituent.	06-09-2011

Francesca Doonan, Co. Cork IE

Patent application number	Description	Published
20110144077	TREATMENT OF RETINAL DEGENERATION - The use of a compound having a gon-4-ene nucleus, said nucleus having attached thereto, in the 13 position, a polycarbon-alkyl radical having 2 to about 16 carbon atoms, said compound containing at least 19 and up to 40 carbon atoms in its carbon-carbon skeleton, in the manufacture of a medicament for the treatment or prevention of a disease or condition characterised by apoptosis or degeneration of mammalian cells.	06-16-2011

Francesca Fallarino, Perugia IT

Patent application number	Description	Published
20110250280	MICROENCAPSULATION PROCESS OF SERTOLI CELLS, MICROCAPSULES OBTAINED AND THEIR USE FOR PREVENTION AND CURE OF TYPE I DIABETES MELLITUS - The invention relates to the use of Sertoli cells (SC) microencapsulated into hydrogel-based microcapsules, for the prevention and/or treatment of Type 1 diabetes mellitus (T1DM) and to a process for producing microcapsules, preferably shaped as microspheres.	10-13-2011

Francesca Fiorenza, Siracusa IT

Patent application number	Description	Published
20110052755	SWEETENER COMPOSITIONS - Provided is a sweetener composition comprising: an extract from the leaves of the	03-03-2011

Francesca Fruttarolo, Ferrara IT

Patent application number	Description	Published
20100035923	VR1 VANILLOID RECEPTOR ANTAGONISTS WITH A IONONIC SUBSTRUCTURE - The invention provides compounds of formula (I), wherein Y, R, n and X are as defined in the description, a process for their preparation and pharmaceutical compositions containing them. The compounds of formula (I) inhibit the Transient Receptor Potential Vanilloid 1 (TRPV1), which plays a pivotal role in the development of post-inflammatory analgesia, therefore they can be used as analgesic and anti-inflammatory drugs.	02-11-2010
20100105740	O-SUBSTITUTED-DIBENZYL UREA-DERIVATIVES AS TRPV1 RECEPTOR ANTAGONISTS - The invention relates to compounds of formula (I) in which R is selected from halogen, alkyl, alkoxy, aryl and heteroaryl; R	04-29-2010

Francesca Gaggini, Geneva CH

Patent application number	Description	Published
20110172266	PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS - The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).	07-14-2011
20110178081	PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS - The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).	07-21-2011
20110178082	PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS - The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).	07-21-2011
20110269757	PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS - The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).	11-03-2011

Francesca Giuntini, Mercatale Val Di Pesa IT

Patent application number	Description	Published
20110112464	MESO-SUBSTITUTED PORPHYRINS - Meso-substituted porphyrins of general formula (I)	05-12-2011

Francesca Gugliesi, Torino IT

Patent application number	Description	Published
20110300529	DETECTION OF IFI16 IN BODY FLUIDS - The present invention relates to methods for the qualitative and/or quantitative determination of interferon inducible protein 16 (IFI 16) in an extracellular form.	12-08-2011

Francesca Iacovacci, Cavenago Brianza IT

Patent application number	Description	Published
20090241471	PROCESS FOR PRODUCING POWDER WAFERS FOR EYE SHADOWS, FACE POWDER, MAKE-UP ARTICLES, BLUSHER, ETC. WITH A MOSAIC EFFECT ACHIEVED BY COMPACTING VARIOUSLY COLOURED PELLETS - There is described a process for producing multicolored solid powder wafers for use in solid beauty products, wherein the solid powder wafers so produced have a mosaic effect.	10-01-2009

Francesca Intonti, Florence IT

Patent application number	Description	Published
20090103884	Method For Producing Rewritable Photonic Devices - Method for the creation of a rewritable photonic device inserted in a photonic crystal (	04-23-2009

Francesca Kuglen, Oakland, CA US

Patent application number	Description	Published
20090277467	STRETCH COMB HAIR RETAINER - A stretch comb hair retainer has opposed combs (	11-12-2009
20100132729	HAIR COMB AND DUAL COMB HAIR ACCESSORY HAVING SAME - An improved hair comb for a dual comb hair accessory (	06-03-2010

Francesca Levi-Schaffer, Jerusalem IL

Patent application number	Description	Published
20080219980	Bi-Specific Complexes for Targeting Cells Involved in Allergic-Type Reactions, Compositions and Uses Thereof - Disclosed are bi-specific complexes aimed at inhibiting mast cells, eosinophils and/or basophils, and thus, at inhibiting allergy-type reactions. In particular, said complexes are best exemplified by bi-specific antibodies, which bind to two targets present in the same cell. One target is the inhibitory receptor IRp60. The second target is a cell-specific activator, e.g. IgE, cKIT, FcεRI, IL5R or CCR3. Binding of the bi-specific antibody to its targets results in the induction of an inhibitory pathway, through the inhibition of the signaling from the activator. Compositions and uses of the bi-specific complexes are also described.	09-11-2008

Francesca Maestrelli, Santiago De Compostela ES

Patent application number	Description	Published
20080220030	Nanoparticles Comprising Chitosan and Cyclodextrin - This invention relates to a system comprising nanoparticles designed for the release of biologically active molecules, where the nanoparticles comprise a) at least 40% by weight of chitosan or a derivative thereof and b) less than 60% by weight of a cyclodextrin or a derivative thereof, where both components a) and b) are mixed, without any covalent bond between them. This system allows for the efficient association of biologically active molecules, as well as their subsequent release in a suitable biological environment.	09-11-2008

Francesca Micoli, Siena IT

Patent application number	Description	Published
20110142876	CONJUGATED VI SACCHARIDES - Two Vi conjugates have been prepared by carbodiimide-mediated synthesis, using adipic acid dihydrazide derivatized CRM	06-16-2011
20110159602	ANALYSIS OF VI SACCHARIDES - Vi saccharide can be assayed in two new ways. First, its proton NMR spectrum can be used, with comparison to an internal Standard permitting quantitative analysis. Second, anion exchange chromatography with amperometric detection can be used on hydrolysed saccharide.	06-30-2011

Francesca Okoye, Menlo Park, CA US

Patent application number	Description	Published
20100331391	ZAP-70 AS PREDICTOR AND MODULATOR OF EFFECTOR FUNCTION OF T CELLS - In this application is described a novel, multiparameter analysis of TCR-coupled signaling and function in resting and activated naive and memory CD4 T cells, revealing a biochemical basis for immunological recall. Results reveal a novel biochemical signature imparted to memory CD4 T cells enabling efficacious responses through increased ZAP-70 expression and reduced accumulation of downstream signaling events.	12-30-2010

Francesca Piccinetti, Siena IT

Patent application number	Description	Published
20080254065	Influenza Virus Vaccines - The invention provides a vaccine for protecting a human patient against infection by a human influenza virus strain, wherein the vaccine comprises an antigen from an avian influenza virus strain that can cause highly pathogenic avian influenza. The antigen can invoke an antibody response in the patient that is capable of neutralising said human influenza virus strain. Whereas the prior art used known non-pathogenic avian strains to generate antibodies in humans against known pathogenic avian strains, the invention uses known pathogenic avian strains to protect against emerging pathogenic human strains. Furthermore, whereas the prior art focused on achieving a close antigenic match between the vaccine strain and the target strain, the invention selects vaccine strains based on their pathogenicity, regardless of any perceived close antigenic relationship to the target strain. As the invention does not require detailed knowledge of an emerging strain, a vaccine can be provided further in advance to reduce the risk and potential effects of a human pandemic outbreak.	10-16-2008

Francesca Pignagnoli, Reggio Emilia IT

Patent application number	Description	Published
20120010309	STORAGE-STABLE POLYOL COMPOSITIONS FOR PRODUCING RIGID POLYISOCYANURATE FOAM - Disclosed is a polyol composition comprising an aliphatic polyester polyol having a hydroxyl value of less than about 100 and prepared by the reaction of at least a polycarboxylic acid with a polyhydroxy compound; an aromatic polyester polyol; a Novolac-type polyether polyol; and a hydrofluorocarbon blowing agent; that may be storage-stable for at least 60 days. This composition may be reacted with a polyisocyanate at an isocyanate index of from about 2.5 to about 4 to form a rigid poly-isocyanurate foam. The foam shows improved cohesion in general and also improved adhesion and a reduced incidence of voids when applied to a metal substrate.	01-12-2012

Francesca Quartieri, Arona IT

Patent application number	Description	Published
20090149457	1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors - There are provided thieno[2,3-c]pyrazole derivatives of formula (I), wherein A is an aryl or heteroaryl ring, on which the substituent-NHZR	06-11-2009

Francesca Quartieri, Arona (no) IT

Patent application number	Description	Published
20090124605	Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors - Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.	05-14-2009

Francesca Quattrocchio, Amsterdam NL

Patent application number	Description	Published
20090217413	PLANT GENETIC SEQUENCES ASSOCIATED WITH VACUOLAR PH AND USES THEREOF - The present invention relates generally to the field of plant molecular biology and agents useful in the manipulation of plant physiological or biochemical properties. More particularly, the present invention provides genetic and proteinaceous agents capable of modulating or altering the level of acidity or alkalinity in a cell, group of cells, organelle, part or reproductive portion of a plant. Even more particularly, the present invention contemplates methods and agents for modulating or altering pH levels in the vacuole of a cell, group of cells, organelle, part or reproductive portion of a plant. The present invention further provides genetically altered plants, plant parts, progeny, subsequent generations and reproductive material including flowers or flowering parts having cells exhibiting an altered vacuolar pH compared to a non-genetically altered plant. The present invention still further provides methods for modulating or altering flower color in a plant. Even more particularly, the present invention provides for down regulation of pH in a plant which results in a bluer color in the plant; especially in the flower	08-27-2009
20090293144	PLANT NUCLEIC ACIDS ASSOCIATED WITH CELLULAR pH AND USES THEREOF - The present invention relates generally to the field of plant molecular biology and agents useful in the manipulation of plant physiological or biochemical properties. More particularly, the present invention provides genetic and proteinaceous agents capable of modulating or altering the level of acidity or alkalinity in a cell, group of cells, organelle, part or reproductive portion of a plant. Genetically altered plants, plant parts, progeny, subsequent generations and reproductive material including flowers or flowering parts having cells exhibiting an altered cellular pH compared to a non-genetically altered plant are also provided.	11-26-2009

Francesca Reineri, Cuneo IT

Patent application number	Description	Published
20110178393	Process for the Preparation of Aqueous Solutions of Hyperpolarized Molecules - The invention relates to a one-step process for the preparation of aqueous solutions of hyperpolarized molecules in which, in a single step, the said hyperpolarized molecules are separated from the crude solution by means of a fast phase-transfer extraction and isolated in an impurity-free aqueous solution, ready for use in the MRI diagnostic imaging of organs, region or tissues of the human or animal body.	07-21-2011

Francesca Rosella, Rome IT

Patent application number	Description	Published
20110119812	FABRIC CONSTRUCTIONS WITH SENSORY TRANSDUCERS - A fabric construction includes sensory transducers, such as light-emitting diodes, for sensory effects while maintaining the look and feel of a conventional fabric item. The construction is especially adapted for implementation as a garment. The construction has a fabric layer and an appliqué on a front surface of the fabric layer. A plurality of electrical sensory transducers are arranged in a desired pattern with an electrical harness electrically interconnecting the sensory transducers to a drive and control circuit. The transducers and harness are located between a rear surface of the appliqué and a front surface of the fabric layer, while the drive and control circuitry is positioned at a rear surface of the fabric layer. The fabric layer and appliqué are bonded together to seal the transducers and harness in place. Releasable connectors extend through the fabric layer to operatively connect the harness to the drive and control circuit.	05-26-2011

Francesca Sardelli, Roma IT

Patent application number	Description	Published
20090012169	Combined use of L-carnitine, acetyle L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratospermia - L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salts, or their pharmaceutically acceptable salts, are used in combination to treat oligoasthenoteratosperia including oligospermia, asthenospermia, and teratospermia.	01-08-2009

Francesca Schiaretti, Parma IT

Patent application number	Description	Published
20110308519	DRY POWDER FORMULATION COMPRISING AN ANTIMUSCARINIC DRUG - The invention provides dry powder formulations suitable for the inhalatory administration by means of a dry powder inhaler, comprising an antimuscarinic drug as active ingredient. The invention also provides processes for the preparation of such a formulation and method for the prevention and/or treatment of a wide range of conditions including respiratory disorders by administering such a formulation.	12-22-2011

Francesca Sciré-Scappuzzo, Lexington, MA US

Patent application number	Description	Published
20110006957	METHOD AND APPARATUS FOR A HIGH-PERFORMANCE COMPACT VOLUMETRIC ANTENNA - A wide-bandwidth antenna (e.g., a rib-dipole antenna) includes a first pole formed by a first conductive member and/or a second pole formed by a second conductive member. The antenna also includes an antenna feed between the first conductive member and the second conductive member. The antenna also includes at least one electrically conductive element including a surface. A portion of the surface is electrically connected to, and extends from, the first conductive member or the second conductive member. The at least one electrically conductive element is capable of conducting a current that generates a magnetic field. The magnetic field lowers a total reactance of the antenna, thereby resulting in enhanced performance of the antenna and more efficient use of volume.	01-13-2011

Francesca Sciré-Scappuzzo, Lexington, MA US

Patent application number	Description	Published
20090096704	Non-Cutoff Frequency Selective Surface Ground Plane Antenna Assembly - Described is an apparatus and method for reducing noise in an information bearing signal is provided. A feeding element receives dual-polarized wideband electromagnetic signals. The feeding element is coupled to a Non-Cutoff Frequency Selective Surface ground plane. The Non-Cutoff Frequency Selective Surface ground plane allows for a line-of-sight signal and a surface wave to cancel. The Non-Cutoff Frequency Selective Surface ground plane can be a metal plate with a plurality of corrugations. The corrugations can be concentric rings, each corrugation having a predetermined height and a predetermined spacing from adjacent corrugations.	04-16-2009
20100258919	SEMICONDUCTOR PATCH ANTENNA - A semiconductor patch antenna for microwave radiation having a wide pin-junction or pn-junction with the depletion region or embodiments having a separating buried oxide (SiO	10-14-2010
20110006957	METHOD AND APPARATUS FOR A HIGH-PERFORMANCE COMPACT VOLUMETRIC ANTENNA - A wide-bandwidth antenna (e.g., a rib-dipole antenna) includes a first pole formed by a first conductive member and/or a second pole formed by a second conductive member. The antenna also includes an antenna feed between the first conductive member and the second conductive member. The antenna also includes at least one electrically conductive element including a surface. A portion of the surface is electrically connected to, and extends from, the first conductive member or the second conductive member. The at least one electrically conductive element is capable of conducting a current that generates a magnetic field. The magnetic field lowers a total reactance of the antenna, thereby resulting in enhanced performance of the antenna and more efficient use of volume.	01-13-2011
20110267252	Non-Cutoff Frequency Selective Surface Ground Plane Antenna Assembly - Described is an apparatus and method for reducing noise in an information bearing signal is provided. A feeding element receives dual-polarized wideband electromagnetic signals. The feeding element is coupled to a Non-Cutoff Frequency Selective Surface ground plane. The Non-Cutoff Frequency Selective Surface ground plane allows for a line-of-sight signal and a surface wave to cancel. The Non-Cutoff Frequency Selective Surface ground plane can be a metal plate with a plurality of corrugations. The corrugations can be concentric rings, each corrugation having a predetermined height and a predetermined spacing from adjacent corrugations.	11-03-2011

Francesca Selmin, Milan IT

Patent application number	Description	Published
20090253754	Fast dissolving films and coatings for controlled release of flavors, active pharmaceutical ingredients, food substances, and nicotine - A fast-dissolving film for use as a platform for the delivery of material to the oral cavity, comprising a film forming agent; a plasticizing agent; and a fast-dissolving, water-soluble agent; and methods for producing same.	10-08-2009

Francesca Serravalle, Sorrey GB

Patent application number	Description	Published
20110136473	COMMUNICATION SYSTEM - A cellular communications system is provided in which a user device sends a Service Request to a Mobility Management Entity together with parameter data that depends on the service that is requested. The Mobility Management Entity then determines from the parameter value if AS security is required to provide the requested service. If it is not, then the Mobility Management Entity accepts the Request without providing security parameters for establishing another signalling radio bearer so that an existing signalling radio bearer is used to provide the requested service. If it is, then the Mobility Management Entity accepts the Request and provides security parameters for establishing another signalling radio bearer to be used in providing the requested service.	06-09-2011

Francesca Sparvoli, Milan IT

Patent application number	Description	Published
20090042779	Purified Extract of an Alpha-Amylase Inhibitor From Phytoemagglutinin-Essentially Free Beans, Process for Its Extraction and Compositions Containing It - The invention relates to the use of beans essentially free from phytohemagglutinin for extracting the alpha-amylase inhibitor (hereinafter also “phaseolamin”), the extract enriched in phaseolamin, the highly purified extract, and also the dietetic and pharmaceutical compositions that contain it; the invention also relates to a process for preparing the above extract and for the immobilisation of phaseolamin on an inert solid support.	02-12-2009

Francesca Tarchino, Varazze ( Savona) IT

Patent application number	Description	Published
20090264451	6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS - The present invention is directed to novel 6-1H-imidazo-2-aryl and 2-heteroaryl quinazoline and quinoline of formula I, corresponding salts and solvates thereof, to a process for their preparation and to the use of this compounds and corresponding pharmaceutical composition for the treatment of pain and inflammatory related disorders. Compounds of the invention have been proven highly effective in the pharmacological treatment of both inflammatory and neuropathic pain, in addition to striking anti-inflammatory properties. Their effectiveness in interfering with COX-2 and inflammatory cytokines expressions and production, highlights them as interesting compounds also for the treatment of cancer in addition to several inflammatory diseases.	10-22-2009
20110257209	6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS - The present invention is directed to novel 6-1H-imidazo-2-aryl and 2-heteroaryl quinazoline and quinoline of formula I, corresponding salts and solvates thereof, to a process for their preparation and to the use of this compounds and corresponding pharmaceutical composition for the treatment of pain and inflammatory related disorders. Compounds of the invention have been proven highly effective in the pharmacological treatment of both inflammatory and neuropathic pain, in addition to striking anti-inflammatory properties. Their effectiveness in interfering with COX-2 and inflammatory cytokines expressions and production, highlights them as interesting compounds also for the treatment of cancer in addition to several inflammatory diseases.	10-20-2011

Francesca Usberti, Parma IT

Patent application number	Description	Published
20110146677	AEROSOL FORMULATION FOR COPD - The stable aerosol solution formulations comprising glycopyrronium chloride are useful for administration to patients with COPD and other respiratory conditions.	06-23-2011
20110150782	COMBINATION THERAPY FOR COPD - Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate.	06-23-2011
20110150783	AEROSOL FORMULATION FOR COPD - Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.	06-23-2011
20110150784	COMBINATION THERAPY FOR COPD - Aerosol formulations comprising glycopyrronium chloride in combination with formoterol may be administered by means of a pressurized metered dose inhaler (pMDI) for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium chloride and the formoterol components. Optionally, the formulation may further comprise beclometasone dipropionate.	06-23-2011

Francesca Venturini, Duebendorf CH

Patent application number	Description	Published
20080224807	Horizontal magnet arrangement with radial access - A magnet arrangement comprising a superconducting magnet coil system (M) for generating a magnetic field in the direction of a horizontal z-axis in a working volume (V) disposed along the z-axis about z=	09-18-2008
20090002107	Superconducting magnet arrangement with hysteresis free field coil - A magnet arrangement (M, M′, M″, M′″) for generating a magnetic field in the direction of a z-axis in a working volume (V) disposed on the z-axis about z=0, with a magnet coil system (A, A′, A″, A′″) which comprises one or more superconducting magnet partial coil systems (A	01-01-2009

Francesca Viti, Sesto San Giovanni (mi) IT

Patent application number	Description	Published
20110288058	Methods for Preventing or Reducing Colon Carcinogenesis - The present invention is directed in part to methods of preventing or reducing colon carcinogenesis comprising administering to a patient at risk of colorectal cancer, a pharmaceutical preparation comprising disclosed chemopreventive. In another aspect, the invention is directed to methods attenuation of oxygen free radicals comprising administrating to a patient in need thereof an antioxidant effective amount of a compound represented by formula I, IIa or IIb as disclosed herein.	11-24-2011
20110288177	Methods for Preventing or Reducing Colon Carcinogenesis - The present invention is directed in part to methods of preventing or reducing colon carcinogenesis comprising administering to a patient at risk of colorectal cancer, a pharmaceutical preparation comprising a chemopreventive agent disclosed herein.	11-24-2011
20120015033	ANTISENSE COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease.	01-19-2012

Francesca Zazzeroni, Montesilvano Colle IT

Patent application number	Description	Published
20080247956	IDENTIFICATION OF NOVEL FACTORS THAT BLOCK PROGRAMMED CELL DEATH OR APOPTOSIS BY TARGETING JNK - Methods and compositions for modulating apoptosis by acting on the c-Jun-N-terminal kinase (JNK) pathway and assays for the isolation of agents capable of modulating apoptosis, including modulators of the JNK pathway are disclosed. A method of modulating JNK pathway independent of Gadd46β is disclosed. Methods and compositions are presented for the preparation and use of novel therapeutic compositions for modulating diseases and conditions associated with elevated or decreased apoptosis.	10-09-2008